Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-21
2009-06-30
Solola, Taofiq A (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S338000, C514S367000, C514S394000, C514S456000, C546S114000, C546S282400, C548S159000, C548S307400, C549S362000
Reexamination Certificate
active
07553848
ABSTRACT:
bis-Bicyclic amides and derivatives thereof and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.
REFERENCES:
patent: 2468457 (1949-04-01), Orem et al.
patent: 614375 (1962-08-01), None
patent: 615892 (1962-10-01), None
patent: 63094248 (1988-04-01), None
patent: WO 03/049702 (2003-06-01), None
patent: WO 2004/069792 (2004-08-01), None
Szadowski et al., Dyes and Pigments (1997) vol. 33(2), pp. 97-105.
Boger, et al., J Org Chem., “Parallel Synthesis and Evaluation of 132(+)-1,2,9,9a-Tetrahydrocyclopropal[c]benz[e]indol-4-one(CBI)Analogues of CC-1065 and the Duocarmycins Defining the Contribution of the DNA-Binding Domain” 66, 6654-6661 (2001).
Boger et al., J Am Chem Soc., “Total Synthesis of Distamycin A and 2640 Analogues: A Solution-Phase Combinatorial Approach to the Discovery of New, Bioactive DNA Binding Agents and Development of a Rapid, High-Throughput Screen for Determining Relative DNA Binding Affinity or DNA Binding Sequence Selectivity”, 122, 6382-6394 (2000).
Warpehoski, et al., J Med Chem., “Stereoelectronic Factors Influencing the Biological Activity and DNA Interaction fo Synthetic Antitumor Agents Modeled on CC-1065” 31, 590-603 (1988).
Puchkov, et al., Beilstein “3-hydroxy-naphthalene-2-carboxylic acid 1,3-dihydro-benzo[1,2,5]thiadiazol-4(or 5)-ylamide” Nov. 29, 1988 (English translation) J Org Chem USSR, 13, 756-760 (1977)—abstract.
Kim, et al., Beilstein “naphthalene-2-carboxylic acid quinolin-3-ylamide” May 16, 2000; Syn Lett 12, 1957-1959 (1999)—abstract.
Kamel, et al., Beilstein “3-hydroxy-naphthalene-2-carboxylic acid 1(3)H-benzoimidazol-5-ylamide” Nov. 28, 1988, J Prakt Chem., 31 100-105 (1966)—abstract.
Smith, et al., J Am Chem Soc., “The Thermal Breakdown of Diaryltetrazoles” 80, 17 4647-4654 (1958).
Wilson, J Am Chem Soc., “The So-Called ‘Anthraquinonediimines’; Symmetrical Trisubstituted Triazines” 70, 5 1901-1903 (1948).
Hulme Christopher
Ncube Mqhele Vellah
Norman Mark H.
Ognyanov Vassil I.
Pettus Liping H.
Amgen Inc.
Person Richard V.
Solola Taofiq A
LandOfFree
Vanilloid receptor ligands and their use in treatments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vanilloid receptor ligands and their use in treatments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vanilloid receptor ligands and their use in treatments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4147762